Objectives Current evidence indicates that the pharmacokinetic profile of rivaroxaban is not
significantly impacted by body weight. However, real-world data are needed to better assess …

Introduction Current evidence indicates that rivaroxaban may be a safe and effective
alternative to warfarin among patients with nonvalvular atrial fibrillation (NVAF) and obesity …

Background Current evidence suggests that rivaroxaban may be well tolerated and effective
in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited …

Background: Although rivaroxaban has demonstrated consistent drug levels in normal
weight and obese patients, sufficient confirmation of equal clinical effectiveness and safety is …

Background There are limited data regarding clinical outcomes and healthcare resource
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …

Aims To compare clinical outcomes of rivaroxaban and warfarin in patients with nonvalvular
atrial fibrillation (NVAF) and concurrent obesity and diabetes. Methods Patients aged≥ 18 …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

This sub-analysis of the XAPASS, a prospective, single-arm, observational study, aimed to
evaluate relationships between body mass index (BMI) and safety (major bleeding and all …

This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major
bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with …

Background: Direct oral anticoagulants (DOACs) have been increasingly preferred over
warfarin; however, The International Society of Thrombosis and Hemostasis recommended …